Hyperfine (HYPR) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed Hyperfine (HYPR) over the past year, losing 35.9% versus a loss of 55.0%. Over five years, SERA leads with a -81.4% price change compared with -90.5% for HYPR. Hyperfine is the larger company by market cap ($100.8 million vs $82.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | SERA |
|---|---|---|
| Share price | $0.9501 | $2.10 |
| Market cap | $100.76M | $82.80M |
| 1-day change | +1.06% | +3.91% |
| YTD return | -3.97% | -31.53% |
| 1-year return | -55.02% | -35.87% |
| 5-year return | -90.54% | -81.38% |
| EPS (TTM) | $-0.37 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.22 | $3.95 |
| 52-week low | $0.754 | $1.56 |
| Distance from 52-week high | -57.20% | -46.86% |
| Analyst consensus | none | none |
| Avg. price target upside | +113.66% | +162.03% |
| Average volume | 765.15K | 27.84K |
| Shares outstanding | 90.99M | 38.48M |
| Employees | 102 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SERA has outperformed HYPR by 19.1 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
HYPR vs SERA FAQ
Which is bigger, Hyperfine or Sera Prognostics?
Hyperfine (HYPR) is larger, with a market capitalization of $100.76M compared with $82.80M for Sera Prognostics (SERA).
Which stock has performed better over the past year, HYPR or SERA?
SERA returned -35.87% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and Sera Prognostics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Hyperfine and Medical Specialities for Sera Prognostics.